Will others avoid US 'patent dance' after Sandoz biosimilars court win?
This article was originally published in SRA
Executive Summary
A US District Court has ruled that Novartis unit Sandoz did nothing wrong by not engaging in the disclosure and dispute resolution process laid out by the Biologics Price Competition and Innovation Act – the law that established the abbreviated licensure pathway for biosimilars. The ruling, on 19 March, may spur other companies to do the same1.